Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 10/20 | 0.55 |
| ▸ | TACR3 | P29371 | 15/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.51 |
| ▸ | LDHA | P00338 | 1/20 | 0.49 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.49 |
| ▸ | DHODH | Q02127 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848628 | 0.87 | TACR3 (0.56) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL6853012 | 0.86 | TACR3 (0.64) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5908826 | 0.85 | TACR2 (0.56) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL6848956 | 0.85 | TACR2 (0.61) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5466472 | 0.84 | TACR2 (0.57) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL6853329 | 0.84 | TACR2 (0.57) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5908692 | 0.84 | TACR2 (0.55) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL6855404 | 0.83 | TACR2 (0.54) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5945331 | 0.83 | TACR2 (0.67) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL6851699 | 0.83 | TACR3 (0.67) | TACR2TACR3KCNH2OPRM1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | claimed |
| US-6780875-B2 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-08-24 | — | — | US | disclosed |
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2003-11-13 | — | — | US | disclosed |
| CN-1407850-A | Process for converting storage reserves of dicot seeds into compositions comprising one or more gene products | UNICROP LTD (FI) | 2003-04-02 | — | — | CN | disclosed |
| CN-1406225-A | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GLAXO SMITHKLINE S P A (IT) | 2003-03-26 | — | — | CN | disclosed |
| EP-1131295-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | Smithkline Beecham S.p.A. (IT) | 2001-09-12 | — | — | EP | disclosed |
| WO-2000031037-A1 | QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM S.P.A. (IT) | 2000-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212101-A1 | Quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | KCNH2, KCNA6, KCNA3 | TACR2 21/4885TACR3 86/4885KCNH2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.